Sales rise for Celebrex and Bextra after Vioxx withdrawal
Tuesday, November 30th 2004, 2:35 pm
News On 6
WASHINGTON (AP) _ Pfizer's Celebrex gained a majority of sales for new-generation painkillers in the month after Merck & Co. yanked Vioxx due to safety concerns, according to IMS Health, a pharmaceutical information company.
Pfizer's other cox-2 inhibitor, Bextra, gained fewer prescriptions in October, and in November confronted heightened scrutiny of its safety.
Merck faces a flood of lawsuits after Vioxx was linked to increased risk of heart attack and stroke and the company withdrew it from the market Sept. 30. Analysts estimate the company's legal liabilities could reach $18 billion.
In October, the first full month of data after the Vioxx withdrawal, sales of Celebrex topped $260 million, or 63.5 percent of the market for cox-2 inhibitors, according to IMS Health data. In September, Celebrex had accounted for 48.7 percent of the market for the new-generation painkillers.
Bextra sales in October totaled $148 million or 36 percent of the $409 million cox-2 inhibitor market. In September, Bextra had 23.5 percent of that market.
For the first 10 months of 2004, Celebrex remained the top selling cox-2 inhibitor with 19.8 million prescriptions filled. Sales of Bextra, by contrast, totaled 10.9 million prescriptions in the same time period.
Rheumatologists had expressed some wariness about prescribing Bextra to patients, fearing it caused the same type of heart woes as Vioxx.
When they came onto the market, the cox-2 inhibitor drugs were praised for blocking the enzyme that causes the pain and swelling of arthritis inflammation. The drugs, however, were selective in their targets, and helpfully bypassed the cox-1 enzyme that helps the stomach maintain a protective lining.
A preliminary study discussed at the American Heart Association's annual meeting in early November indicated Bextra more than doubled the risk of heart and stroke among heart disease patients taking the painkiller.
Pfizer dismissed that study's findings in a press release, calling them ``unsubstantiated conclusions'' that had not been subjected to independent scientific review. The company, however, alerted regulators that it will add to its packaging a black box warning _ the Food and Drug Administration's most strident alert _ to warn consumers of a potentially fatal skin reaction linked to Bextra.
An FDA advisory committee in mid-February will review all available data on cox-2 inhibitors, including Bextra, Celebrex and Vioxx.
The data includes a placebo-controlled trial involving 3,600 patients that tries to determine whether Celebrex prevents colon polyps and another that tests the popular painkiller as a possible Alzheimer's treatment.
Independent panels reviewing those trials have not yet seen signs that Celebrex is as harmful to the heart as Vioxx.